Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Direct Diagnostic Tests for Lyme Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Schutzer, S. E., Body, B. A., Boyle, J., Branson, B. M., Dattwyler, R. J., Fikrig, E., Gerald, N. J., Gomes-Solecki, M., Kintrup, M., Ledizet, M., Levin, A. E., Lewinski, M., Liotta, L. A., Marques, A., Mead, P. S., Mongodin, E. F., Pillai, S., Rao, P., Robinson, W. H., Roth, K. M., Schriefer, M. E., Slezak, T., Snyder, J. L., Steere, A. C., Witkowski, J., Wong, S. J., Branda, J. A. 2018

Abstract

Borrelia burgdorferi was discovered to be the cause of Lyme disease in 1983, leading to seroassays. The 1994 serodiagnostic testing guidelines predated a full understanding of key B. burgdorferi antigens and have a number of shortcomings. These serologic tests cannot distinguish active infection, past infection, or reinfection. Reliable direct-detection methods for active B. burgdorferi infection have been lacking in the past but are needed and appear achievable. New approaches have effectively been applied to other emerging infections and show promise in direct detection of B. burgdorferi infections.

View details for PubMedID 30307486